Cover Image
市場調查報告書

A型/B型流感的開發中產品分析

Influenza A And B Infections - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 253672
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
A型/B型流感的開發中產品分析 Influenza A And B Infections - Pipeline Review, H2 2014
出版日期: 2014年09月10日 內容資訊: 英文 44 Pages
簡介

流感是因哺乳類、鳥類感染流感病毒(RNA病毒的一種)而發病。最常見的徵兆有發冷和發熱、喉嚨痛、肌肉痛、頭痛、咳嗽、四肢無力感/疲勞、整體不舒服等。流感容易與類似的病(感冒等)混淆,不過是會依不同種類病毒而引起嚴重疾病。感染後1∼2日後徵兆突然出現(發冷、畏寒為一般初期徵兆)。如果感染了,要充分休息和補充水分,避開酒精和香煙,可能的話應接受藥物治療。

本報告提供全球各國的A型/B型流感病毒感染治療方法的開發中產品之開發情形相關分析、開發中產品的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

A型/B型流感概要

治療藥的開發

  • A型/B型流感開發中產品的概要

各企業開發中的A型/B型流感治療藥

大學/研究機關研究中的A型/B型流感治療藥

臨床實驗的後期階段產品

藥物研發、前臨床階段的產品

A型/B型流感治療藥:開發中的產品一覽(各企業)

A型/B型流感治療藥:研究中的產品一覽(各大學/研究機關)

A型/B型流感治療藥的開發企業

  • 富山化學工業
  • Crucell N.V.
  • Colby Pharmaceutical Company
  • Cocrystal Discovery, Inc.
  • Beech Tree Labs, Inc.

A型/B型流感:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 各投藥法
  • 分子的各類型

藥物簡介

  • favipiravir
  • JVRS-100 + 通用流感疫苗
  • CR-9114
  • A型/B型流感病毒的抗體
  • 流感醫藥品

A型/B型流感治療藥:最新的藥物簡介

A型/B型流感治療藥:暫停開發的產品

A型/B型流感相關產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5529IDB

Summary

Global Markets Direct's, 'Influenza A And B Infections - Pipeline Review, H2 2014', provides an overview of the Influenza A And B Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza A And B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A And B Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza A And B Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Influenza A And B Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Influenza A And B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Influenza A And B Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Influenza A And B Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Influenza A And B Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A And B Infections Overview
  • Therapeutics Development
    • Pipeline Products for Influenza A And B Infections - Overview
    • Pipeline Products for Influenza A And B Infections - Comparative Analysis
  • Influenza A And B Infections - Therapeutics under Development by Companies
  • Influenza A And B Infections - Therapeutics under Investigation by Universities/Institutes
  • Influenza A And B Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Influenza A And B Infections - Products under Development by Companies
  • Influenza A And B Infections - Products under Investigation by Universities/Institutes
  • Influenza A And B Infections - Companies Involved in Therapeutics Development
    • Daiichi Sankyo Company, Limited
    • Beech Tree Labs, Inc.
    • MI.TO. Technology S.r.L.
  • Influenza A And B Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • laninamivir - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BTL-TML001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Viral RNA Polymerase for Influenza - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Influenza - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Influenza A And B Infections - Recent Pipeline Updates
  • Influenza A And B Infections - Dormant Projects
  • Influenza A And B Infections - Product Development Milestones
    • Featured News & Press Releases
      • Aug 01, 2014: Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate
      • May 08, 2014: Biota Provides Update on BARDA Contract for Laninamivir Octanoate
      • Dec 20, 2013: Biota Reports That Laninamivir Octanoate is Approved for the Prevention of Influenza in Japan
      • Dec 05, 2013: Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere
      • Aug 05, 2013: FDA approves supply of GSK's quadrivalent influenza vaccine in US
      • Jun 11, 2013: Biota Initiates Phase II Trial Of Laninamivir Octanoate For Treatment Of Influenza In Adults
      • Jun 10, 2013: Sanofi's New Four-Strain Influenza Vaccine Fluzone Receives FDA Approval For Broad Age Range Of Children And Adults
      • Apr 11, 2013: Sanofi Pasteur Announces Acceptance Of Marketing Authorization Application For Quadrivalent Formulation Of Vaxigrip In Europe
      • Apr 03, 2013: GSK's Four-strain Seasonal Influenza Vaccine Receives Marketing Authorization In Germany And UK
      • Apr 01, 2013: BioCryst Pharma Receives Preliminary Comment Letter From FDA For Peramivir
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Influenza A And B Infections, H2 2014
  • Number of Products under Development for Influenza A And B Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Influenza A And B Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2014
  • Influenza A And B Infections - Pipeline by Beech Tree Labs, Inc., H2 2014
  • Influenza A And B Infections - Pipeline by MI.TO. Technology S.r.L., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Influenza A And B Infections Therapeutics - Recent Pipeline Updates, H2 2014
  • Influenza A And B Infections - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Influenza A And B Infections, H2 2014
  • Number of Products under Development for Influenza A And B Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top